Formycon AG (ETR:FYB)
24.90
-0.05 (-0.20%)
At close: Dec 8, 2025
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the quarter ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 48.07M, down -17.19% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
48.07M
Revenue Growth
-17.19%
P/S Ratio
9.15
Revenue / Employee
192.30K
Employees
250
Market Cap
439.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Formycon AG News
- 4 days ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq
- 4 days ago - EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Wallstreet:Online
- 14 days ago - EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy - Wallstreet:Online
- 18 days ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista
- 18 days ago - EQS-News: Ranibizumab Biosimilar Epruvy launched in Germany - Wallstreet:Online
- 21 days ago - EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent (dupilumab) adds another growth driver to the biosimilar portfolio - Wallstreet:Online
- 23 days ago - Formycon AG 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 24 days ago - Positioning Barbados as the Caribbean's Life Sciences Hub - Benzinga